QR код

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)

<i>Clostridioides</i> <i>difficile</i> infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of r...

Повний опис

Збережено в:
Автори: Sahil Khanna, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa von Moltke, Mark H. Wilcox
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2022-09-01
Серія:Antibiotics
Предмети:
<i>Clostridioides</i> <i>difficile</i> infection (CDI)
SER-109
microbiome therapeutics
Firmicutes
microbial diversity
recurrent CDI
Онлайн доступ:https://www.mdpi.com/2079-6382/11/9/1234
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси